PublizoomAward notice Supplies
Aflibercept (eylea)
Notice published in Dutch. The AI analysis summarises it for you in your language.
- Public buyer
- AZ Delta vzw
Roeselare - Place of performance
- 8800 Roeselare, West Flanders
- Amount awarded
- €4,754,694 excl. VAT
- Planned end of contract
- 31 December 2025
- Bids received
- 1
- Form
- Framework agreement
Multi-year contract: the buyer places orders as needs arise. - Procedure
- Negotiated procedure without prior publication
The buyer consulted a few companies directly: it is no longer possible to take part. - Publication
- 20 February 2025
- Notice language
- Dutch
AI analysis: go for it or not?
Summary in English, criteria, documents to provide and a GO / NO GO verdict in one minute.
Unlimited analyses during the 14-day Pro trial, no card needed.
Description
De aanbestedende overheid wenst een raamovereenkomst te sluiten voor de aankoop van aflibercept (eylea). Het contract wordt gesloten voor een periode van 1 jaar met ingang 01/01/2025.
Awarded to
- Bayer NV BCE/KBO 0404.754.571
CPV codes
European codes that classify what the contract is about. They are how we find the tenders for your trade.
33600000
Winning prices for comparable contracts
- A quarter below
- €269,390
- Median
- €449,863
- A quarter above
- €962,736
Amounts awarded (excl. VAT) over the last 3 years for 58 contracts in the same CPV group (3360…), excluding framework agreements. Half of the contracts fall between the two quartiles. TED source: mostly contracts above the EU thresholds, so amounts tend to be high.
Similar contracts already awarded
| Contract | Winner | Amount |
|---|---|---|
| Nintedanib en pirfenidon AZ Delta vzw · 6 October 2026 |
Accord Healthcare BV Aurobindo NV |
€1,080,061 |
| Aflibercept AZ Delta vzw · 8 September 2026 |
Celltrion Healthcare Netherlands BV | €4,424,940 |
| Denosumab SC AZ Delta vzw · 16 July 2026 |
Amgen NV | €389,080 |
| Tocilizumab IV AZ Delta vzw · 18 June 2026 |
Celltrion Healthcare Netherlands BV | €385,370 |
| Parenterale cytostatica AZ Delta vzw · 7 April 2026 |
Celltrion Healthcare Netherlands BV Sandoz NV Accord Healthcare BV Arega Pharma NV Aurobindo NV Fresenius Kabi NV Pharmanovia Benelux BV Grindeks-Kalceks Belgium BV Viatris BV EG NV Pharma Mar BV Roche NV |
€3,950,688 |
Source : TED – Office des publications de l'Union européenne © Union européenne, données retraitées. Reference 114861-2025.